CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
J. Wang,Z. Wang,L. Wu,B. Li,Y. Cheng,X. Li,X. Wang,L. Han,X. Wu,Y. Fan,Y. Yu,D. Lv,J. Shi,J. Huang, S. Zhou,B. Han,G. Sun,Q. Guo,Y. Ji,X. Zhu,S. Hu,W. Zhang,Q. Wang,Y. Jia,Z. Wang,Y. Song,J. Wu,M. Shi, X. Li,Z. Han,Y. Liu,Z. Yu,A. Liu,X. Wang,C. Zhou,D. Zhong,L. Miao, Z. Zhang,H. Zhao,J. Yang,D. Wang, Y. Wang, Q. Li,X. Zhang,M. Ji,Z. Yang,J. Cui,B. Gao,B. Wang,H. Liu, L. Nie,M. He,S. Jin,W. Gu,Y. Shu,T. Zhou,J. Feng,X. Yang,C. Huang,B. Zhu,Y. Yao, Y. Wang, X. Kang,S. Yao,P. Keegan JOURNAL OF THORACIC ONCOLOGY（2021）
Key words
anti-PD-1, 1st line treatment for NSCLC, Toripalimab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper